Quale sarebbe il prezzo per Curatis Holding AG (CURN)

Il prezzo per Curatis Holding AG (CURN) è $25.88

Qual è la capitalizzazione di mercato per Curatis Holding AG (CURN)

La capitalizzazione di mercato per Curatis Holding AG (CURN) è $137.20M

Curatis Holding AG (CURN) Prezzo e Capitalizzazione di Mercato

Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.

Il prezzo per CURN	Attivo B	Capitalizzazione del mercato a B	Risultati
$960,580 $137.20M	NVDA	$5.092T	+3,711,406.67%
$862,881 $137.20M	AAPL	$4.574T	+3,333,917.02%
$789,960 $137.20M	GOOG	$4.188T	+3,052,164.10%
$682,023 $137.20M	MSFT	$3.616T	+2,635,112.79%
$531,626 $137.20M	AMZN	$2.818T	+2,054,005.52%

Il prezzo per CURN

Attivo B

Capitalizzazione del mercato a B

Risultati

$960,580 $137.20M